Press enter or click to view image in full size
In recent reports, light and sound that pulse 40 times per second are a frequent subject. A study from 2025 associated with MIT indicates that certain individuals with Alzheimer’s disease who used daily gamma sensory stimulation maintain their mental processing and physical brain density for a longer duration than researchers anticipated. At this time Cognito Therapeutics conducts a Phase 3 trial across the nation to test this concept. For a precise summary, the scope is more limited than news titles suggest. Gamma brain waves are a significant subject for investigators but the initial results are subtle and quantified by instruments rather than being large in scale. “Slower decline” is not identical to “reversal” or “cure”. To understand the situation, one must examine what the information confirms and what it does not.
What did the 2025 long term 40 Hz study actually find?
The findings describe a reduction in the speed of decline rather than a reversal of the condition. In the extended monitoring period, patients who continue daily use of 40 Hz stimulation through light and sound exhibit less loss of brain tissue. As a result those patients show a slower reduction in mental test scores compared to typical expectations and some of the effects remain over a period of time — those are objective and quantifiable results — but they are also preliminary and come from small sets of participants. They represent a decline that is less steep, which is not the same as a person regaining their lost memories — this difference is the primary point of the research but it often is absent from news summaries.
How does 40 Hz gamma stimulation work in the brain?
Gamma waves are the rhythms in the brain with the highest frequency and 40 Hz is at the center of that range. When a person receives light and sound that pulses 40 times every second, large clusters of nerve cells start to fire their electrical signals in coordination with that pulse — this is a process that scientists call the frequency following response. In experiments involving mice, this coordinated activity has two specific effects. It triggers microglia, which are cells that manage the immune response and waste removal in the brain. It appears to help the systems that clear out proteins like amyloid. The current hypothesis is that moving the brain into a gamma rhythm helps the organ maintain its own cleanliness. It is a logical theory with an increasing amount of supporting data but it is not a proven certainty.
From mouse models to humans — the OVERTURE & HOPE trials
If one moves from studying mice to studying humans, carefulness is necessary. The OVERTURE study by Cognito Therapeutics is a controlled experiment of daily sensory stimulation for patients with Alzheimer’s. It reports that the group receiving treatment maintains more brain mass and experiences a slower loss of daily function. By using a separate analysis, researchers also find that the treated group keeps the structure of the corpus callosum — the thick bundle of fibers connecting the two sides of the brain — in better condition than the control group. To see if those results are consistent in a larger population, the company is now conducting the HOPE Phase 3 trial. Until the results of that trial are available, the appropriate attitude is one of curiosity without total certainty.
What do “slower atrophy” and “preserved white matter” mean for a patient?
Those terms refer to specific physical measurements of the brain and the connection between the measurements and the daily life of a patient is still a subject of study. “Slower atrophy” indicates that the brain loses less volume during the timeframe of the study than the brains in a comparison group. “Preserved white matter” indicates that the physical connections between different areas of the brain experience less damage. Both results are positive because they are based on physical data instead of the opinions of the patients. They do not prove that a person will have a significant or dependable improvement in how they remember facts, make plans or perform daily tasks. A treatment is able to improve the appearance of a brain scan while the difference in daily life remains small. For families who are considering their choices, this distinction is an important fact.
Why this is a clinical device story, not a biohacking shortcut
To treat Alzheimer’s disease is not the same as using light and sound for general health. The research regarding Alzheimer’s involves a medical device that is subject to government rules. It requires a specific dose, daily use for many months and observation by doctors. It is under investigation as a form of medicine — this is different from a mobile application for a consumer to use for stress or for sleep.
Press enter or click to view image in full size
How we think about gamma at 6th
By recognizing the value of this research, we do not apply its findings to our own services. In our office in Sofia and through the free 6th Mind app, we use audio visual entrainment which includes gamma frequencies — but we provide clinical services for individuals who have depression, anxiety and insomnia rather than Alzheimer’s disease. We do not provide treatment for dementia and no information in this text indicates that an app is able to treat that condition. As shown by the research on Alzheimer’s disease, investigators are testing the process of using AVE therapy to lead the brain toward a specific rhythm in controlled studies. With those developments, we have a basis for limited certainty in this method and a requirement to ensure our statements are accurate. If a person seeks a method for stress or sleep that uses light and sound without medication, a free app is a suitable tool for the specific needs. And this application is distinct from the treatment of a disease where the nervous system breaks down over time.
Interested in how technology can enhance mental health and cognitive performance?
Subscribe to our newsletter for weekly deep-dives: https://6thmind.substack.com/subscribe